New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
Article excerpt
Highlighted: the sentence this signal was extracted from
Nearly three times as many patients taking Taltz and Zepbound achieved ≥ 50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind TOGETHER-PsA study Improvements in disease activity at one year follow statistically superior outcomes observed with Taltz and Zepbound vs. Taltz alone at Week 36 primary endpoint Detailed data were featured as an oral presentation at ACR Convergence 2026 and simultaneously published in Arthritis & Rheumatology INDIANAPOLIS, Nov. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced detailed 52-week results showing improved and durable efficacy from the TOGETHER-PsA Phase 3b open-label clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with active psoriatic arthritis (PsA) and obesity or overweight with at least one additional weight-related comorbid condition. New detailed exploratory analyses showed treatment with Taltz and Zepbound used together maintained or further improved outcomes across disease activity, patient-reported and metabolic measures through Week 52. As previously reported, treatment with Taltz and Zepbound met the primary and all key secondary endpoints for statistically significant superiority to Taltz alone at 36 Weeks. The 52-week findings were presented at the...
Keep reading with a free account
The rest of this article, and every signal for Eli Lilly, is in your free account.
